Galderma · Injectable Aesthetics · Australia & New Zealand

What the ANZ market actually says about injectables

Social-listening study · 2025-01-01 to 2026-08-11 · compiled 12 August 2026

280verbatim quotes
96sources
96/96URLs resolving
16evidenced themes
53%negative or fearful

Overview

Every finding here traces to a named person, on a dated page, at a link that works.

280 verbatim quotes from real Australians and New Zealanders discussing injectable aesthetics, captured between 2025-01-01 and 2026-08-11. Each one carries its platform, date, sentiment and a live source URL. Nothing here is inferred from market reports.

Negative 120 · 43% Fearful 28 · 10% Neutral 52 · 19% Positive 80 · 29%

The themes, by weight of evidence

Click any theme to jump to it. Bar length is quote count.

What this corpus is made of

Patient voice244
Consumer voice25
Practitioner voice11
Australia208
New Zealand54
Dated 2026121
Dated 2025159

87% of quotes come from people who actually had treatment, rather than commentators.

The single biggest complaint is not clinical

The largest negative theme in this corpus — 33 quotes — is not about a product failing. It is about what happens afterwards: results not corrected, complaints redirected to compliance teams, and dissatisfaction attributed to the patient's own anatomy. Clinical fears rank below it.

Market temperature

A normalised market with low trust in the people delivering it.

Injectables are ordinary here — priced against a hair appointment, common among colleagues in their twenties. What is not settled is who to trust, what it should cost, and how long it should last.

Tension 1 · Trust is in the person, not the product

Anxiety concentrates on practitioner competence, not molecules. Satisfaction is attributed to named individuals almost every time it appears.

Tension 2 · Price is discussed constantly, published nowhere

Per-unit prices are compared obsessively across cities, while clinics cannot legally advertise them — so nobody can compare before committing.

Tension 3 · Duration is the promise that breaks

The most concrete disappointment in the corpus is a treatment lasting weeks when months were expected.

Where the voice came from

reddit146
productreview44
facebook38
trustpilot15
clinic sites10
readymind6
body image movement4
realself4
newsweek3
guardian2
lawyers alliance2
adore beauty2
derm lab2
sunrise1
fresha1

What they were talking about

neurotoxin123
ha filler57
unspecified42
category generic17
skin booster13
multi11
hyaluronidase9
adjacent4
biostimulator4

No market-size, growth or forecast figures appear anywhere in this report. Analyst data was deliberately excluded — it is not consumer voice, and the citations attached to it did not survive validation.

Themes · the findings

16 themes carry real evidence. Each one opens to the people who said it.

A theme here means a group of people independently saying the same thing — not a topic we found interesting. Anything with fewer than eight supporting quotes is shown separately and labelled thin, because at that depth it is a hypothesis.

negative33 quotes

When it goes wrong, no one fixes it

"write to the compliance team"

The largest negative cluster in the corpus, and it is not about the product at all — it is about what happens afterwards. People report being asked to email a compliance team to justify why a treatment failed, being offered a discount on more filler to fix asymmetry, and being told an unsatisfactory result reflects their own anatomy. The injury is procedural and relational, not clinical.

  • refusal to correct a poor result
  • paying again to fix their mistake
  • bureaucratic stonewalling
  • being told the result is your anatomy
  • upsold instead of remedied
  • months of unreturned calls
positive31 quotes

I found someone I trust, and that changed everything

"ask for Marilou", "she never upsells me"

The largest positive cluster, and the mirror image of the trust fear. Satisfaction is overwhelmingly attributed to a *named individual*, not a brand or a clinic. What earns trust is specific and repeatable: not being upsold, being given time, being told what will not work, and a long-term rather than per-unit approach.

  • named-practitioner recommendation culture
  • not being upsold
  • thoroughness and taking time
  • long-term approach over unit-selling
  • feeling cared for and at ease
  • honest appraisal of what won't work
Vocabulary in this market
tox neutralanti-wrinkle injections clinicaltweakments neutralbaby Botox aspirationcowboys mockingfrozen shameduck lips mockingfiller moustache mockingaliens mockingOzempic face neutralhad work done neutralthe rabbit hole shame
negative22 quotes

It didn't last anything like as long as I was told

"worn off", "barely lasting 10 weeks"

The single most concrete disappointment: a duration was expected and not delivered. It spans brands, and it is where marketing claims and lived experience visibly diverge — the Daxxify six-month claim is challenged directly and repeatedly, and long-term users report developing resistance.

  • Daxxify's 6-month claim not met
  • toxin resistance after long-term use
  • fast metabolism and exercise
  • 8 weeks vs a 3-6 month claim
  • paying for a top-up to reach the promised duration
negative20 quotes

I can't find out what it costs until I'm in the chair

"$15 a unit", "quoted one amount"

Price is discussed constantly and compared obsessively, per unit and per city. The frustration is less about the amount than the opacity — clinics cannot advertise prices, so consumers cannot compare before committing, and some report the quote changing at the till.

  • price cannot legally be advertised
  • quoted one price, charged another
  • forced to buy a full 1ml
  • cost-of-living pressure
  • per-unit price comparison between cities
  • is cheaper worse?
positive20 quotes

It looks natural and nobody can tell

"people don't clock it", "baby Botox"

The direct answer to the naturalness fear, and it is behaviourally specific: lower doses, staged volume, retained movement, one consistent injector over time. Several report explicitly requesting reduced dosing to preserve expression. This is the evidence base for every 'natural results' reframe.

  • deliberate under-dosing to keep movement
  • baby Botox micro-dosing
  • 0.5ml at a time rather than a full syringe
  • no migration after 9 years
  • compliments without detection
  • same injector over years
fearful18 quotes

I don't know if the person injecting me is qualified

"cowboys", "one-day course"

Consumers cannot assess practitioner competence before treatment and know it. The corpus repeatedly names the one-day course as the only legal prerequisite, debates nurse versus doctor versus dentist, and warns about prescribers who never see the patient. This is anxiety about a system, not about a molecule.

  • one-day training courses
  • nurse vs doctor vs dentist
  • franchise clinics and staff turnover
  • prescriber never seen the patient
  • unqualified people entering the industry
  • reporting to AHPRA
fearful15 quotes

Filler moves, and it may never really leave

"filler moustache", "migration is inevitable"

A belief that HA filler does not fully resolve and quietly spreads — stated as fact, not speculation, and increasingly framed as unavoidable rather than a bad-outcome risk. This is the highest-intensity fear in the corpus and it attaches to the product itself rather than the practitioner.

  • migration described as almost inevitable
  • still present 5+ years later
  • spreading rather than metabolising
  • blindness and vascular risk
  • filler placed intramuscularly
  • granulomas
negative13 quotes

Counterfeit product, and people injecting themselves

"watered down", "from their garage"

Two connected things: fear that the product was fake or diluted when results disappoint, and an active DIY subculture buying toxin online. Three hospitalisations after at-home injections appear in the corpus. This is the cluster with genuine public-safety weight.

  • counterfeit toxin reported in Melbourne
  • suspecting a diluted product
  • buying toxin online and self-injecting
  • botulism hospitalisations
  • home and garage operations
  • which Korean brands are TGA-approved
negative12 quotes

Boosters hurt, cost a lot, and did nothing I could see

"money to burn", "back to baseline"

A specific, product-named cluster covering Rejuran and Profhilo. Complaints concentrate on pain, cost per session, and results too subtle to justify either. Commercially relevant because it is the segment adjacent to Galderma's biostimulator portfolio.

  • Rejuran pain and blunt needles
  • no change to dark circles or tear troughs
  • return to baseline in 6 months
  • Profhilo puffiness and facial droop
  • upsold from filler into a booster
  • injectors abandoning Profhilo
fearful11 quotes

Dissolving didn't undo it — and I regret doing it

"a new set point in their minds"

Dissolving is widely assumed to be the safety net, and this cluster shows it is not experienced that way. People report tissue deflation, incomplete removal, repeat sessions, and — notably — regret at having reversed at all. It matters because 'you can always dissolve it' is the reassurance the category leans on most.

  • mid-cheek deflation after dissolving
  • lumps returning post-dissolve
  • needing repeat dissolving sessions
  • regret after reversal
  • cost of dissolving on top of the filler
  • never dissolve unless you must
fearful11 quotes

I'm afraid it will be obvious, or that I'll look older

"frozen", "duck", "aliens walking around"

The classic naturalness fear, and in this market it is specifically a fear of being *seen* to have had work done, plus a newer fear that early heavy treatment ages you faster. Note the asymmetry: people are afraid of looking overdone, not of the treatment failing.

  • frozen forehead
  • duck lips
  • young faces looking older
  • structural collapse from too much too soon
  • muscle atrophy long-term
  • wanting a fix, not more volume
neutral11 quotes

I'm new to this and don't know who to ask

"looking for recommendations", "why the bloody hell not"

People at the very start, asking openly what to get, who to see and what it will feel like. Strategically the most important theme for the content programme: these are unanswered questions being typed in public, by people with no brand loyalty and no practitioner yet. Every one is a candidate article title, and several ask about pain and subtlety specifically.

  • asking a forum because they know no one who has had it done
  • wanting subtle, specifically not size
  • first-time nerves about pain
  • asking what to expect before booking
  • medical reason rather than cosmetic
  • researching before a milestone birthday
mixed10 quotes

Trying the next toxin along

Active brand experimentation among engaged users, mostly driven by the longevity hunt. Relfydess appears as a genuine post-launch destination. One quote reports Dysport being given after Botox was requested, without consent — a distinct and serious complaint.

  • Botox to Relfydess
  • Botox to Daxxify
  • Letybo to Relfydess
  • Dysport chosen for faster onset
  • product substituted without consent
  • Korean toxins as a value option
positive10 quotes

A good consultation felt completely different

"didn't feel pressured", "honest appraisal"

What a good process actually looks like from the patient's side: options explained, muscles assessed, dosing negotiated, no pressure, and a touch-up offered without argument. Directly counters the aftercare-failure theme, and is the reframe anchor for 'what to expect from a consultation' content.

  • full picture of options before deciding
  • no pressure and no upsell
  • physical assessment before injecting
  • dosing adjusted to what was asked
  • complimentary consultation
  • prompt free touch-up when needed
fearful9 quotes

It made me systemically unwell

"iatrogenic Botox poisoning"

Small but serious: accounts of systemic illness attributed to toxin, including one long-term case and one report of receiving 65 units when 40 were requested. Handle with real care — these are medical claims, and the content response is informed consent and what to escalate, never reassurance that it cannot happen.

  • headaches and low mood after treatment
  • iatrogenic botulism
  • over-dosing without consent
  • no warning of systemic risk
  • symptoms to escalate on
negative8 quotes

The rabbit hole — filters, dysmorphia and warning others off

"the rabbit hole", "a gamble in the name of vanity"

The motivational layer beneath the rest: people questioning why they wanted it, patients arriving with filtered photos, and one practitioner expressing guilt at promoting the category. Includes objection to injectables being framed as equivalent to facials, which is a positioning critique.

  • injectables normalised alongside facials
  • filtered photos as a target
  • self-esteem unchanged after treatment
  • practitioner regret at promoting it
  • warning others away
  • injecting foreign material into your face

Thin themes — real, but under-evidenced

Kept visible rather than deleted. Each is a candidate for targeted follow-up research; none should carry a conclusion on its own.

neutralthin evidence6 quotes

Everyone's doing it now

"mandatory in the Eastern suburbs"

Treatment described as ordinary — priced against a hair appointment and common among colleagues in their twenties. Useful context for tone: this audience does not need persuading that injectables exist or are acceptable, which argues against any content that reads as introductory advocacy.

  • a third of colleagues have had it
  • costs the same as a hair appointment
  • once for the rich and famous
  • celebrities being open about it
  • you can't tell unless it's overdone
positivethin evidence6 quotes

Choosing not to, and being fine with it

A counter-current rejecting anti-ageing pressure altogether. Only 5 quotes, mostly from one blog, so it cannot be treated as a market position — but it is worth watching because it is the audience least reachable by any injectable content.

neutralthin evidence6 quotes

The rules are changing

Consultation-before-prescription requirements, psychological suitability assessment, and NSW complaints reportedly doubling in a year. Only 6 quotes of consumer voice — the regulatory substance is real but under-evidenced here, and would need a dedicated sweep.

neutralthin evidence5 quotes

Can I have this with, or before, that?

Sequencing questions — toxin before a facelift or blepharoplasty consult, stopping before a hair transplant, flying after filler, where threadlifts sit. Only 5 quotes, but they are precise, practical and completely unanswered, which makes them strong future article candidates.

mixedthin evidence5 quotes

Trying skincare or devices instead

People substituting or supplementing with topicals, retinoids, SPF, lasers and patches — including two accounts of topical 'filler' products failing. Thin, but it is the exit route referenced in the injectables-to-skincare switching pathway.

mixedthin evidence5 quotes

Biostimulators as the collagen answer

Sculptra and Radiesse discussed as the route to rebuilding collagen and volume, notably for post-weight-loss laxity, alongside one granuloma concern. Directly relevant to Galderma's portfolio and under-evidenced at 5 quotes — a clear target for a follow-up sweep.

mixedthin evidence5 quotes

Volume loss after weight loss

GLP-1-driven facial volume loss, with filler and biostimulators positioned as the answer. Only 5 quotes despite high Australian GLP-1 adoption, which suggests the corpus under-sampled it rather than the market lacking it. Flagged as a research gap, not a small theme.

fearfulthin evidence5 quotes

Not telling anyone

Pre-emptive defensiveness about vanity and difficulty finding anyone to ask openly. Thin at 5 quotes, but note it is a *disclosure* barrier — it may suppress the very discussion this research depends on.

Brand landscape

61% of this conversation names no brand at all.

171 of 280 quotes discuss "anti-wrinkle injections", "tox", "filler" or "my injector" without naming a product. That is Australia's TGA Schedule 4 advertising restriction showing up directly in consumer language — people cannot be advertised to by brand, so they do not think or search in brands.

What this means for content

Brand-led material will under-perform against how this audience actually searches. Category-level questions — will it look natural, how long does it last, how do I choose an injector — match the language in this corpus. New Zealand is the exception: brand naming is permitted there under the Medicines Act 1981, and NZ clinic sources in this corpus do name products.

Brands named, by mention count

Botox76
Dysport12
Rejuran10
Daxxify9
Profhilo7
Relfydess6
Sculptra6
Xeomin4
Letybo3
Radiesse2
Nabota2
Botulax2
PRP1
Restylane1

Botox functions as the generic term for the whole category. Galderma products appear far less often — too seldom for per-brand sentiment diagnosis, which this report therefore does not attempt.

Who is speaking

patient244
consumer25
hcp11

Practitioner voice is present but small. Where practitioners appear they are usually warning consumers about unqualified injectors.

Switching & exit

Where people go next — including out of the category entirely.

49 quotes describe a move from one thing to another. Two pathways deserve attention beyond the brand switching: people leaving for nothing at all, and people leaving clinics to inject themselves.

fillerdissolver3
clinicDIY3
BotoxRelfydess2
BotoxDaxxify2
fillerfacelift2
Botoxnothing2
injectablesskincare2
nothingfiller2
dissolverfiller2
Botox/DysportRelfydess1
LetyboRelfydess1
Botoxdental splint1
BotoxDysport1
CACIMuse1
fillerProfhilo (upsold)1
fillernothing1
medispasurgeon1
fillerdissolving1
fillerbotox1
BotoxDysport/Xeomin (price driven)1
doctornurse1
medispapain specialist1
topicalsbiostimulator1
fillerbiostimulator1

Adverse events

What people report going wrong, in their own words.

Tagged from the verbatims, not from a clinical checklist — so this is what consumers describe and fear, which is not the same as a regulatory adverse-event register. Experienced and feared events both appear; the quotes distinguish them.

migration6
poor longevity5
asymmetry5
lack of efficacy5
frozen face3
rapid metabolism3
psychological distress3
practitioner incompetence3
systemic toxicity3
headaches2
stinging2
pain2
zero efficacy2
low ROI2
fleeting results2
extreme pain2
blindness2
wasted money2
gaslighting2
poor aftercare2
granulomas2
upselling2
physical pain2
refusal of care2

Serious events including blindness risk, vascular occlusion and systemic toxicity appear in small numbers. They are recorded here because consumers raise them, and because any content touching them must address informed consent rather than reassurance.

Who & where

Australia and New Zealand, metro and regional.

Age-cohort segmentation is not available at this depth — only a minority of quotes carry a reliable age signal, so this report does not present cohort cards. Geography and voice type are well evidenced and shown instead.

Market

Australia208
New Zealand54
Unspecified18

New Zealand is genuinely represented rather than folded into an Australia-dominated view — which matters because the two regulate brand naming in opposite directions.

Voice type

patient244
consumer25
hcp11

Evidence library

All 280 verbatims and all 96 sources, filterable.

This is the working layer. Filter it, search it, and click through to any original page.

Source library

Every URL was checked automatically. live 80 · blocked automated checks 16 · dead 0. No grounding-redirect proxies are present.

Reddit 62

Social platforms 19

Clinic websites 1

Method

How this was built, and what it does not cover.

Capture

Two Gemini Deep Research Max sweeps, three-pass design. The first returned a corpus dominated by one platform, so a second run was commissioned with that platform explicitly closed and review sites, forums, clinic content and press targeted instead. The corpus below is both runs merged and deduplicated.

Validation

Every source URL is resolved over the network before publication. Gemini grounding-redirect citations — short-lived proxies that expire within days — are rejected outright, and any quote carrying one is dropped rather than published with a dead link. Result: 0 dead, 0 redirects.

Deliberate exclusions

No market sizing, growth rates or analyst figures. They are not consumer voice, and the citations attached to them did not survive validation. No price library — prices are quoted throughout the verbatims but were not systematically collected.

Known gaps

Age-cohort signal is thin. GLP-1-driven volume loss, regulatory change, outbound medical tourism and grey-market DIY all appear but with too few quotes to carry a finding — each is shown as a thin theme rather than written up. Instagram and TikTok comments were not readable at scale.

Themes were clustered by reading every verbatim, bottom-up, rather than sorting quotes into a predetermined list. 297 theme assignments across 280 quotes; 8 quotes belong to no theme and are pure price or out-of-scope references.